Hacker News Reader

The article mentions poor incentive structure around development of better disease models as an obstacle for some of the drug categories, is that an area where either the federal govt or the industry as a whole can step in and develop a collective solution?

View on HN

That's certainly what's implied by Scannell's answer to Question 8, but such a solution comes with its own set of limitations related to design by committee.

Small startup teams are still the most effective way to solve hard problems in our society, and so I suspect that any definitive solution would likely be built and sold to the industry by such a team.

Reply on news.ycombinator.com